Hikma intros clindamycin in 5% dextrose injection
The injection is indicated for the treatment of numerous infections.
Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial.
Clindamycin in 5% dextrose injection is indicated for the treatment of numerous infections, including but not limited to septicemia, intra-abdominal infections, lower respiratory infections, gynecological infections, bone and joint infections and skin and skin structure infections.
[Read more: Hikma intros Kloxxado]
Clindamycin injection had a market value of approximately $22 million in the 12 months ending June 2024, per IQVIA.
[Read more: Hikma intros Kloxxado]